Incyte (INCY)
(Delayed Data from NSDQ)
$56.97 USD
-0.15 (-0.26%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $56.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
INCY 56.97 -0.15(-0.26%)
Will INCY be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings
Other News for INCY
RBC Capital Sticks to Its Hold Rating for Incyte (INCY)
Incyte participates in a conference call with JPMorgan
Incyte participates in a conference call with JPMorgan
Incyte Corp. stock outperforms competitors on strong trading day
Incyte Corp. stock underperforms Monday when compared to competitors